Visual Outcome, Cylinder Correction and Patient Satisfaction After Implantation of AT LISA Tri Toric 939MP Intraocular Lenses

NCT ID: NCT02985723

Last Updated: 2018-01-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2016-06-30

Brief Summary

The aim of the present study is to evaluate the postoperative visual acuity for distance, intermediate and near vision as well as the cylinder correction and the patient satisfaction after bilateral implantation of AT LISA tri toric 939MP IOLs.

Conditions

Cataract

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

939MP

AT LISA tri toric 939MP intraocular lens

Group Type: EXPERIMENTAL

AT LISA tri toric 939MP

Intervention Type: DEVICE

Interventions

AT LISA tri toric 939MP

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent
• Man or woman, over 50 years of age
• Healthy eyes with bilateral cataract requiring surgical treatment for both eyes
• Bilateral regular corneal astigmatism (confirmed by topography measurement)
• Only patients requiring intraocular lenses of a power comprised between sphere +0.0 and +28.0 dioptres and between a cylindrical range of +1.0 to +4.0D in both eyes will be able to participate in the trial.
• Biometry measurement/cataract density compatible with the IOLMaster evaluation
• Bilateral uncomplicated cataract surgery and implantation into capsular bag by injector
• Assured follow-up examinations

Exclusion Criteria

• Patients unable to meet the limitations of the protocol or likely of non cooperation during the trial,
• Patients whose freedom is impaired by administrative or legal order,
• Monophtalmic patient.
• Previous ocular surgery, including corneal/refractive surgery,
• Chronic or recurrent uveitis,
• Acute ocular disease or external/internal infection,
• Any kind of macular degeneration and impairment of retina (clinical diagnosis/OCT examination)
• Diabetes with retinal changes,
• Pseudoexfoliation syndrome
• Pathologic myosis
• Irregular astigmatism, especially keratoconus,
• Endothelial corneal dystrophy
• Glaucoma or IOP higher than 21mmHg under ocular hypertension treatment
• Aniridia
• Pseudophakia
• Cornea guttata; keratoplasty
• Amotio operation; anamnesis with vitreous surgery
• Amblyopia
• Intraocular tumours; endotamponade
• Phlogistic intraocular processes or other pre-existing processes that permanently limit the best corrected visual acuity to > 0.3 logMAR
• Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient
• Pupil diameter over 6 mm in mesopic condition
• Corneal opacity

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Carl Zeiss Meditec AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Piovella, Dr

Role: PRINCIPAL_INVESTIGATOR

CMA - Centro Microchirurgia Ambulatoriale

Other Identifiers

2012-A01671-42

Identifier Type: -

Identifier Source: org_study_id